research feed

Every NR4A2 paper, in plain English

PubMed and the Europe PMC preprint servers are queried daily for NR4A2 and NURR1, back to the earliest records. Each abstract is summarised locally by Qwen3.6 35B and tagged by relevance to a parent of an NR4A2 child. Source links go straight to the paper.

subscribe (Atom feed) · high and medium relevance only

registered clinical trials

Every ClinicalTrials.gov study whose record mentions NR4A2 or NURR1. Most use NURR1 as a Parkinson's biomarker rather than testing anything for this syndrome, so read the conditions line. Studies still open come first. Last checked 2026-09-14.

completed or inactive (4) ›
medium2015-07-05 · Chinese medical journal

Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.

Zhang LM, Sun CC, Mo MS, Cen L, Wei L, Luo FF, Li Y, Li GF, Zhang SY, Yi L, Huang W, Liu ZL, Le WD, Xu PY

Dopamine agonist medications increase Nurr1 (NR4A2) gene expression in the blood cells of Parkinson's patients. This effect occurs both in living patients taking these drugs and in laboratory cultures treated with pramipexole. The findings suggest that dopamine agonists may protect brain neurons by boosting NR4A2 levels.

  • Dopamine agonists significantly raise Nurr1 mRNA levels in patient blood cells.
  • L-dopa treatment also increases Nurr1 expression compared to untreated patients.
  • Pramipexole rapidly boosts Nurr1 levels in cultured blood cells within hours.
  • Increased Nurr1 may explain how dopamine drugs protect dopaminergic neurons.
medium2015-06-29 · Proceedings of the National Academy of Sciences of the United States of America

Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.

Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, Nguyen QT, Sohn M, Kim WG, Han M, Jeong I, Kim KS, Lee EH, Tu Y, Naffin-Olivos JL, Park CH, Ringe D, Yoon HS, Petsko GA, Kim KS

Two existing antimalarial drugs, amodiaquine and chloroquine, activate the Nurr1 protein to protect dopamine neurons and reduce inflammation in rats with Parkinson's disease. These treatments improve movement behaviors in the animal model without causing dyskinesia-like side effects.

  • Amodiaquine and chloroquine directly bind to and activate the Nurr1 receptor.
  • Activation boosts dopamine neuron gene expression and reduces neuroinflammation.
  • Treatments improve motor deficits in a rat model of Parkinson's disease.
  • No dyskinesia-like side effects are observed in the treated animals.
medium2015-06-29 · Nature immunology

The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells.

Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang Z, Zhu T, Peace D, Quigley JG, Wu W, Zhao YY, Qian Z

The transcription factor Foxm1 maintains blood stem cell stability by directly activating the NR4A2 gene, and reducing Foxm1 levels disrupts this balance. This study identifies a direct molecular link between Foxm1 and NR4A2 in human cells, confirming that NR4A2 expression is regulated upstream by Foxm1.

  • Foxm1 directly binds to the NR4A2 gene promoter to drive its transcription.
  • Reducing Foxm1 decreases NR4A2 levels and disrupts blood stem cell stability in human cells.
  • Restoring NR4A2 expression reverses the defects caused by low Foxm1 levels.
  • Low Foxm1 correlates with myelodysplastic syndrome, a blood disorder.
medium2015-05-01 · EMBO molecular medicine

Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.

Oh SM, Chang MY, Song JJ, Rhee YH, Joe EH, Lee HS, Yi SH, Lee SH

Delivering Nurr1 and Foxa2 genes via virus in mice protects dopamine neurons and improves movement for at least one year. This preclinical study shows that these two factors work together to shield brain cells from damage.

  • Nurr1 and Foxa2 protect dopamine neurons from toxicity when expressed together.
  • Gene therapy using viruses delivered these factors to mouse brains effectively.
  • Motor behaviors improved significantly in the Parkinson's disease mouse model.
  • Protection lasted for at least one year in the treated animals.
high2015-05-01 · Congenital anomalies

Microdeletion 2q23.3q24.1: exploring genotype-phenotype correlations.

Milani D, Sabatini C, Manzoni FM, Ajmone PF, Rigamonti C, Malacarne M, Pierluigi M, Cavani S, Costantino MA

This case report describes a 13-year-old girl with a genetic deletion on chromosome 2 that includes the NR4A2 gene, linking this specific genomic change to developmental delay and behavioral disorders. The authors identify NR4A2 as a likely contributor to the neurological symptoms observed in this patient.

  • A 13-year-old girl has a de novo deletion on chromosome 2q23.3q24.1.
  • The deletion includes the NR4A2 gene, which is expressed in neuronal cells.
  • Clinical features include mild developmental delay and behavioral disorders.
  • This case helps define the neurological impact of losing the NR4A2 gene.
medium2015-04-01 · Stem cells (Dayton, Ohio)

Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET1- and JMJD3-dependent epigenetic control manner.

He XB, Kim M, Kim SY, Yi SH, Rhee YH, Kim T, Lee EH, Park CH, Dixit S, Harrison FE, Lee SH

Vitamin C promotes the development of dopamine neurons in fetal brain tissue by triggering specific epigenetic changes that activate genes controlled by Nurr1. This process relies on the enzymes TET1 and JMJD3 to modify DNA and histones, making these genes more accessible for expression.

  • Vitamin C boosts dopamine neuron differentiation in embryonic midbrain stem cells.
  • The effect depends on epigenetic modifications by TET1 and JMJD3 enzymes.
  • Nurr1 activity increases as gene promoters become more accessible via these changes.
  • Mice lacking the Vitamin C transporter show reduced dopamine neuron formation.
  • This mechanism links cellular metabolism directly to neural development pathways.
medium2015-03-27 · PloS one

A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).

Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O

A drug that activates the Nurr1 protein protects dopamine-producing neurons and reduces brain inflammation in rats with a Parkinson's disease model. This preclinical study demonstrates that boosting Nurr1 activity can prevent nerve cell loss and calm immune cells in the brain.

  • The Nurr1 agonist SA00025 entered the rat brain and activated dopamine-related genes.
  • Treatment partially protected dopamine neurons from damage caused by inflammation and toxins.
  • The drug reduced markers of microglial and astrocyte activation in the brain.
  • This is a preclinical animal study, not a human clinical trial.
medium2015-03-10 · Biochemical and biophysical research communications

Direct conversion of human fibroblasts into dopaminergic neural progenitor-like cells using TAT-mediated protein transduction of recombinant factors.

Mirakhori F, Zeynali B, Rassouli H, Salekdeh GH, Baharvand H

Researchers successfully converted human skin cells into dopaminergic neural progenitor-like cells using protein transduction and small molecules. This method generates cells that express key midbrain markers, including NURR1, offering a potential source for cell replacement therapies in neurodegenerative diseases.

  • Human fibroblasts convert directly into dopaminergic progenitor-like cells using SOX2 and LMX1a proteins.
  • Generated cells express midbrain markers like NURR1, PITX3, and TH after differentiation.
  • The technique uses TAT-mediated protein transduction combined with small molecules in 3D culture.
  • This approach offers a potential alternative strategy for cell therapy in neurodegenerative disorders.
lower-relevance papers (32) ›
low2015-06-12 · Neuropathology : official journal of the Japanese Society of Neuropathology

Localization of nuclear receptor subfamily 4, group A, member 3 (NR4A3) in Lewy body disease and multiple system atrophy.

Kon T, Miki Y, Tanji K, Mori F, Tomiyama M, Toyoshima Y, Kakita A, Takahashi H, Utsumi J, Sasaki H, Wakabayashi K

NR4A3 protein accumulates specifically within the abnormal protein clumps found in Parkinson's disease and multiple system atrophy, but not in other neurodegenerative conditions. This suggests NR4A3 is a marker for alpha-synuclein pathology rather than a direct cause of the diseases studied here.

  • NR4A3 accumulates in Lewy bodies and glial inclusions in Parkinson's and MSA.
  • NR4A3 co-localizes with phosphorylated alpha-synuclein in these disease-specific inclusions.
  • NR4A3 is absent in tauopathies, TDP-43 proteinopathies, and polyglutamine diseases.
  • The study uses human brain tissue from patients with neurodegenerative disorders.
low2015-06-09 · Mechanisms of ageing and development

Age-related gene expression changes in substantia nigra dopamine neurons of the rat.

Parkinson GM, Dayas CV, Smith DW

This study identifies age-related declines in dopamine neuron function in rats, driven by reduced expression of the transcription factor Nurr1 (NR4A2) and altered neurotrophic signaling. These findings suggest that functional changes in dopamine pathways occur independently of cell death during aging.

  • Rat substantia nigra dopamine neurons show significant gene expression changes with age.
  • Nurr1 expression decreases as rats age, potentially driving functional decline.
  • Neurotrophic factor signaling and tyrosine hydroxylase regulation are altered in aging neurons.
  • Functional deficits may precede or occur without frank neuron loss.
low2015-06-01 · Advanced healthcare materials

Microsphere-Incorporated Hybrid Thermogel for Neuronal Differentiation of Tonsil Derived Mesenchymal Stem Cells.

Patel M, Moon HJ, Jung BK, Jeong B

Researchers successfully differentiated tonsil-derived stem cells into neurons using a 3D hydrogel that releases growth factors over time. The system produced high levels of neuronal markers, including Nurr-1, demonstrating a potential method for generating neural tissue in the lab.

  • Tonsil stem cells differentiate into neurons within a brain-mimicking 3D hydrogel scaffold.
  • Controlled release microspheres deliver growth factors over 12 to 18 days.
  • Cells express high levels of Nurr-1 and other neuronal biomarkers.
  • The method shows promise for tissue engineering and regenerative medicine applications.
low2015-05-28 · The Journal of biological chemistry

Generation of Dopamine Neurons from Rodent Fibroblasts through the Expandable Neural Precursor Cell Stage.

Lim MS, Chang MY, Kim SM, Yi SH, Suh-Kim H, Jung SJ, Kim MJ, Kim JH, Lee YS, Lee SY, Kim DW, Lee SH, Park CH

Researchers successfully convert mouse skin cells into expandable neural precursor cells that can be directed to become dopamine-producing neurons using specific genetic factors. These engineered neurons function correctly in laboratory settings and show therapeutic potential in rat models of Parkinson's disease.

  • Mouse fibroblasts convert into highly expandable neural precursor cells using Wernig factors and Bcl-xL.
  • Adding Nurr1 and Foxa2 drives these precursors to mature into functional midbrain dopamine neurons.
  • The engineered neurons exhibit presynaptic dopamine functions in vitro.
  • Therapeutic potential is assessed in Parkinson disease model rats.
low2015-05-20 · The Journal of neuroscience : the official journal of the Society for Neuroscience

Opposing role for Egr3 in nucleus accumbens cell subtypes in cocaine action.

Chandra R, Francis TC, Konkalmatt P, Amgalan A, Gancarz AM, Dietz DM, Lobo MK

This study investigates how the transcription factor Egr3 regulates behavioral responses to cocaine in specific mouse brain cells, noting that it also influences the expression of NR4A2. The research demonstrates opposing effects of Egr3 depending on whether it acts in dopamine D1 or D2 receptor-expressing neurons. This work focuses entirely on addiction mechanisms in mice and does not address NR4A2-related syndromes or potential treatments for them.

  • Egr3 levels change differently in two types of mouse brain cells after cocaine exposure.
  • Increasing Egr3 in D1 neurons enhances cocaine reward, while decreasing it in D2 neurons blunts it.
  • Cocaine alters Egr3 binding to the NR4A2 gene promoter in specific mouse neurons.
  • The study uses mouse models and does not involve human patients or clinical data.
  • Findings relate to addiction biology rather than developmental disorders or NR4A2 syndrome.
low2015-05-14 · Neuroscience letters

Association between NR4A2 genetic variation and schizophrenia: A comprehensive systematic review and meta-analysis.

Liu H, Fu Y, Ren J, Yu S, Liu H, Jiang P, Dong Y, Li H

NR4A2 gene variations are not strongly linked to schizophrenia risk based on current evidence, with no significant association found across multiple genetic models in a large review of studies.

  • No clear link between NR4A2 variants and schizophrenia risk
  • Five variants found only in people with schizophrenia
  • Meta-analysis included 3027 participants across seven studies
  • Findings suggest need for larger, better-designed studies
  • Results do not support NR4A2 as a major schizophrenia risk factor
low2015-05-10 · Journal of molecular neuroscience : MN

Nur77 Was Essential for Neurite Outgrowth and Involved in Schwann Cell Differentiation After Sciatic Nerve Injury.

Zhang W, Zhu X, Liu Y, Chen M, Yan S, Mao X, Liu Z, Wu W, Chen C, Xu X, Wang Y

This rat study shows that the protein Nur77 helps peripheral nerves repair themselves after injury by supporting Schwann cell differentiation and axon regeneration. Blocking Nur77 impairs this healing process, highlighting its role in peripheral nerve maintenance rather than central dopaminergic pathways.

  • Nur77 levels rise in rat sciatic nerves after injury.
  • The protein localizes to both axons and Schwann cells.
  • Inhibiting Nur77 reduces Schwann cell myelinization.
  • Blocking Nur77 slows axon regeneration in injured nerves.
  • This is a peripheral nerve study, not central dopaminergic.
low2015-05-07 · The Journal of biological chemistry

Nuclear Receptor Nr4a2 Promotes Alternative Polarization of Macrophages and Confers Protection in Sepsis.

Mahajan S, Saini A, Chandra V, Nanduri R, Kalra R, Bhagyaraj E, Khatri N, Gupta P

This study demonstrates that the Nr4a2 protein helps regulate immune responses by shifting macrophages toward an anti-inflammatory state, which protects mice from severe sepsis. It identifies a specific mechanism where Nr4a2 directly activates genes associated with this protective immune phenotype.

  • Nr4a2 induces an anti-inflammatory macrophage phenotype in response to inflammatory signals.
  • The protein directly binds to and activates the arginase 1 gene promoter.
  • Increasing Nr4a2 levels improves survival rates in mouse models of sepsis.
  • This research focuses on innate immunity rather than dopaminergic neuron function.
low2015-05-06 · Glia

Age-dependent Müller glia neurogenic competence in the mouse retina.

Löffler K, Schäfer P, Völkner M, Holdt T, Karl MO

This study shows that mouse Müller glia cells can be reprogrammed to generate new neurons in a lab dish, but this ability declines as the animal ages. The regenerated cells resemble amacrine neurons rather than photoreceptors, and most progeny do not fully mature into functional neurons.

  • Mouse Müller glia regenerate neurons only in juvenile stages, not older mice.
  • Regenerated cells express neuronal markers but likely become amacrine-like cells.
  • Most regenerated cells remain in a de-differentiated state rather than fully maturing.
  • This model helps study limits of mammalian retinal regeneration.
  • Findings are specific to retinal biology and unrelated to NR4A2 motor symptoms.
low2015-05-01 · Stem cells (Dayton, Ohio)

Epigenetic regulation contributes to urocortin-enhanced midbrain dopaminergic neuron differentiation.

Huang HY, Chiu TL, Chang HF, Hsu HR, Pang CY, Liew HK, Wang MJ

Urocortin promotes the differentiation of midbrain dopaminergic neurons in rat brain tissue and cell cultures by modifying chromatin structure to increase the expression of key developmental genes. This process involves inhibiting histone deacetylases, which releases repressor complexes from gene promoters, thereby enhancing the transcription of factors like Nurr1 and Tyrosine Hydroxylase.

  • Urocortin increases dopaminergic neuron numbers in rat midbrain precursor cultures.
  • The mechanism involves epigenetic modification via histone deacetylation inhibition.
  • UCN enhances expression of Nurr1, Foxa2, and Pitx3 transcription factors.
  • In vivo rat studies confirm increased dopaminergic neuron differentiation with UCN treatment.
low2015-04-30 · Stem cells international

Neural Progenitor Cells Derived from Human Embryonic Stem Cells as an Origin of Dopaminergic Neurons.

Noisa P, Raivio T, Cui W

Researchers successfully generate midbrain dopaminergic neurons from human embryonic stem cells using specific chemical signals. This method provides a scalable source of these neurons for potential cell-based therapies in neurodegenerative diseases like Parkinson's.

  • Human embryonic stem cells differentiate into neural progenitors using Dorsomorphin.
  • These progenitors further develop into dopaminergic neurons with midbrain identity markers.
  • The process uses FGF8 and SHH to induce specific neuronal subtypes.
  • This technique offers an unlimited cell source for potential Parkinson's disease treatments.
low2015-04-26 · Atherosclerosis

The neuron-derived orphan receptor 1 (NOR1) is induced upon human alternative macrophage polarization and stimulates the expression of markers of the M2 phenotype.

De Paoli F, Eeckhoute J, Copin C, Vanhoutte J, Duhem C, Derudas B, Dubois-Chevalier J, Colin S, Zawadzki C, Jude B, Haulon S, Lefebvre P, Staels B, Chinetti-Gbaguidi G

NOR1 is a protein that increases in human macrophages when they become anti-inflammatory (M2), and it helps turn on genes that support this protective state. Silencing NOR1 reduces key anti-inflammatory markers, showing it plays a direct role in regulating macrophage function in human tissues.

  • NOR1 increases in human anti-inflammatory macrophages
  • NOR1 boosts expression of anti-inflammatory genes
  • Reducing NOR1 weakens the protective macrophage state
  • NOR1 may regulate genes involved in tissue repair
  • Findings are specific to human macrophages, not mice
low2015-04-23 · The Journal of steroid biochemistry and molecular biology

Nuclear receptor 4A (NR4A) family - orphans no more.

Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB

This review describes the NR4A family of proteins as regulators of cellular stress and homeostasis with potential roles in neurological, metabolic, and inflammatory diseases. It highlights that while natural ligands are unknown, synthetic molecules can activate these receptors, suggesting future therapeutic opportunities for conditions like neurodegeneration.

  • NR4A1, NR4A2, and NR4A3 regulate cellular stress responses and homeostasis.
  • These receptors influence neurological, metabolic, cardiovascular, and immune functions.
  • Synthetic molecules can act as agonists or antagonists for these receptors.
  • Future drugs targeting NR4A may treat neurologic and inflammatory diseases.
low2015-04-09 · PloS one

Chronic Toxoplasma gondii in Nurr1-null heterozygous mice exacerbates elevated open field activity.

Eells JB, Varela-Stokes A, Guo-Ross SX, Kummari E, Smith HM, Cox AD, Lindsay DS

In mice with one copy of the Nurr1 gene, a common parasitic infection worsens hyperactivity and alters fear responses. This suggests that environmental factors like infection can exacerbate behavioral symptoms in individuals with NR4A2 variations by affecting dopamine pathways.

  • Toxoplasma gondii infection increases open field activity in mice with one Nurr1 copy.
  • The hyperactivity effect is significantly worse in heterozygous mice compared to normal mice.
  • Infection abolishes fear of predators in normal mice but only partially affects mutant males.
  • Antibody levels correlate with behavioral changes, showing an inverted U-shaped relationship.
  • Results link Nurr1 deficiency and infection to dopamine-related behavioral alterations.
low2015-04-09 · Molecular pharmacology

The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB.

De Miranda BR, Popichak KA, Hammond SL, Jorgensen BA, Phillips AT, Safe S, Tjalkens RB

A synthetic compound called C-DIM12 reduces inflammatory gene expression in microglial cells by activating the NR4A2 (Nurr1) protein. This activation prevents the binding of pro-inflammatory factors to DNA, thereby suppressing the release of inflammatory signals.

  • C-DIM12 activates Nurr1 to inhibit inflammatory genes in microglia.
  • The effect disappears when Nurr1 is removed, confirming its role.
  • The compound stabilizes corepressor proteins that block inflammation.
  • This study uses only cell cultures, not animals or humans.
low2015-04-01 · Frontiers in cellular neuroscience

Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells' differentiation in vitro and in neurochemical models of Parkinson's disease.

Carrieri C, Forrest AR, Santoro C, Persichetti F, Carninci P, Zucchelli S, Gustincich S

The study shows that Nurr1 regulates a specific RNA molecule (AS Uchl1) that helps produce the UCHL1 protein, which is often reduced in Parkinson's disease. This RNA is down-regulated in Parkinson's models, suggesting it is part of the stress response in dopaminergic neurons.

  • Nurr1 directly regulates AS Uchl1 RNA levels in dopaminergic cells.
  • AS Uchl1 increases translation of UCHL1, a protein linked to Parkinson's.
  • AS Uchl1 levels drop significantly in Parkinson's disease models.
  • This links Nurr1 biology to UCHL1 regulation and cellular stress.
low2015-03-26 · Thrombosis and haemostasis

NR4A receptors up-regulate the antiproteinase alpha-2 macroglobulin (A2M) and modulate MMP-2 and MMP-9 in vascular smooth muscle cells.

Rodríguez-Calvo R, Ferrán B, Alonso J, Martí-Pàmies I, Aguiló S, Calvayrac O, Rodríguez C, Martínez-González J

NR4A receptors regulate vascular health by increasing alpha-2 macroglobulin, which inhibits enzymes that remodel tissue. This mechanism operates in blood vessel cells and involves direct transcriptional control of the A2M gene.

  • NR4A receptors up-regulate alpha-2 macroglobulin in vascular smooth muscle cells.
  • Increased A2M leads to decreased activity of MMP-2 and MMP-9 enzymes.
  • The study focuses on vascular biology, not neurological development or function.
  • No findings relate to NR4A2-related neurodevelopmental syndromes or treatments.
low2015-03-25 · Biology of reproduction

Activation of Mouse Cumulus-Oocyte Complex Maturation In Vitro Through EGF-Like Activity of Versican.

Dunning KR, Watson LN, Zhang VJ, Brown HM, Kaczmarek AK, Robker RL, Russell DL

Versican, a protein found in healthy mouse egg cells, acts like EGF to support egg maturation in the lab, with unique timing and gene effects that may improve egg quality. It boosts key genes involved in egg development and maintains their activity longer than EGF alone.

  • Versican mimics EGF to help egg cells mature in the lab
  • It boosts genes linked to egg quality and expansion
  • Versican works longer and differently than EGF
  • Its effects match those seen in natural egg development
  • May improve in vitro egg maturation techniques
low2015-03-09 · The Journal of biological chemistry

Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent Cytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative Stress-induced Necrosis.

Watanabe T, Sekine S, Naguro I, Sekine Y, Ichijo H

This study identifies a specific cellular mechanism where oxidative stress triggers NR4A2 to move from the nucleus to the cytoplasm, promoting cell death through a non-apoptotic necrotic pathway. The findings clarify how NR4A2 functions in stress responses but do not provide evidence for clinical treatment or human outcomes.

  • NR4A2 promotes oxidative stress-induced necrosis via ASK1-p38 signaling.
  • Phosphorylation causes NR4A2 to translocate from nucleus to cytoplasm.
  • This cell death pathway is independent of caspases and RIP kinases.
  • The research focuses on molecular mechanisms in cell lines, not humans.
low2015-03-06 · Frontiers in aging neuroscience

Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease.

Esteves M, Cristóvão AC, Saraiva T, Rocha SM, Baltazar G, Ferreira L, Bernardino L

Retinoic acid delivered via nanoparticles protects dopamine-producing neurons in a mouse model of Parkinson's disease. The treatment reduces neuron loss and increases the expression of Nurr1, a protein related to NR4A2 function.

  • The study uses a mouse model, not human patients or clinical trials.
  • Retinoic acid nanoparticles protect dopamine neurons from damage in mice.
  • Treatment increases Nurr1 levels, supporting neuron survival and function.
  • This is preclinical research with no direct evidence for NR4A2 syndrome treatment.
low2015-03-01 · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Wnt/β-catenin signal pathway mediated Salidroside induced directional differentiation from mouse mesenchymal stem cells to nerve cells].

Guo C, Liu R, Zhao HB, Qin GH

Salidroside directs mouse stem cells to become nerve-like cells by activating the Wnt/beta-catenin and calcium signaling pathways. This process increases the expression of Nurr1, a protein related to NR4A2, alongside other neuronal markers.

  • Salidroside triggers stem cell differentiation into neuronal cells in mouse models.
  • The drug activates Wnt/beta-catenin and calcium signaling pathways to drive this change.
  • Expression of Nurr1 and other neuronal markers increases significantly during differentiation.
  • Blocking these pathways prevents the formation of nerve-like cells.
low2015-02-18 · Journal of inflammation (London, England)

Orphan nuclear receptor NR4A2 induces transcription of the immunomodulatory peptide hormone prolactin.

McCoy JM, Walkenhorst DE, McCauley KS, Elaasar H, Everett JR, Mix KS

This study identifies prolactin as a direct target gene of NR4A2 in joint cells, suggesting a mechanism by which NR4A2 may drive inflammation and tissue growth in arthritis. The findings describe a specific molecular pathway involving immune modulation within the synovium.

  • NR4A2 directly increases prolactin production in human joint cells.
  • Prolactin influences inflammation, cell survival, and proliferation pathways.
  • This pathway links NR4A2 to arthritis progression mechanisms.
  • The research focuses on inflammatory joint disease, not neurodevelopment.
low2015-02-06 · PloS one

A genome-wide association study for clinical mastitis in first parity US Holstein cows using single-step approach and genomic matrix re-weighting procedure.

Tiezzi F, Parker-Gaddis KL, Cole JB, Clay JS, Maltecca C

This study identified specific regions on chromosomes 2, 14, and 20 linked to mastitis resistance in dairy cows, with genes involved in immune response, inflammation, and mammary gland function. These findings may help improve breeding for disease resistance but do not directly relate to human NR4A2-related syndrome.

  • Chromosomes 2, 14, and 20 contain genes linked to mastitis in cows
  • Genes on chromosome 2 include NR4A2, involved in immune regulation
  • Immune and inflammatory pathways are key to mastitis resistance
  • Findings may inform breeding but not directly applicable to human NR4A2 syndrome
  • No direct therapeutic implications for human neurodevelopmental disorders
low2015-02-02 · Nature neuroscience

Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area.

Koo JW, Mazei-Robison MS, LaPlant Q, Egervari G, Braunscheidel KM, Adank DN, Ferguson D, Feng J, Sun H, Scobie KN, Damez-Werno DM, Ribeiro E, Peña CJ, Walker D, Bagot RC, Cahill ME, Anderson SA, Labonté B, Hodes GE, Browne H, Chadwick B, Robison AJ, Vialou VF, Dias C, Lorsch Z, Mouzon E, Lobo MK, Dietz DM, Russo SJ, Neve RL, Hurd YL, Nestler EJ

Chronic opiate exposure reduces BDNF expression in the brain's reward center by altering epigenetic marks and decreasing NURR1 levels. This study identifies a specific molecular mechanism linking drug addiction to changes in gene regulation involving NR4A2.

  • Morphine lowers BDNF in the VTA via epigenetic modifications at gene promoters.
  • NURR1 expression decreases, contributing to reduced BDNF and behavioral changes.
  • The study focuses on opiate addiction mechanisms, not NR4A2-related syndrome treatment.
low2015-02-01 · Molecular immunology

Porphyromonas gingivalis HSP60 peptides have distinct roles in the development of atherosclerosis.

Jeong E, Kim K, Kim JH, Cha GS, Kim SJ, Kang HS, Choi J

Peptide 14 from Porphyromonas gingivalis HSP60 reduces atherosclerosis in mice by boosting protective regulatory T-cells, while peptide 19 worsens it by promoting inflammatory Th1 cells. This effect is linked to how each peptide shapes immune cell activity, especially through the genes Nr4a1 and Nr4a2.

  • Peptide 14 reduces atherosclerosis and boosts protective T-cells
  • Peptide 19 increases atherosclerosis and drives inflammatory T-cells
  • Nr4a2 is linked to the protective immune response
  • Different peptides activate distinct immune pathways
  • Dendritic cells respond uniquely to each peptide
low2015-01-20 · Autism research : official journal of the International Society for Autism Research

T-Brain-1--A Potential Master Regulator in Autism Spectrum Disorders.

Chuang HC, Huang TN, Hsueh YP

This study identifies NR4A2 as one of four transcription factors regulated by TBR1, a gene known to cause autism spectrum disorders. It suggests that TBR1 controls a genetic cascade involving NR4A2 that may contribute to the development of autism.

  • TBR1 regulates NR4A2 among other transcription factors in autism pathogenesis.
  • The study links TBR1 deficiency to altered expression of key neuronal genes.
  • NR4A2 appears as part of a broader regulatory network, not the primary focus.
  • Research uses mouse models and literature reviews, with no human clinical data.
low2015-01-01 · Advances in neurobiology

Hormonal modulation of catecholaminergic neurotransmission in a prenatal stress model.

Pallarés ME, Antonelli MC

Prenatal stress alters dopamine and norepinephrine signaling in offspring brains, with effects that change significantly before and after puberty due to hormonal shifts. These findings highlight how early environmental factors can disrupt neurotransmitter systems and reproductive health through interactions with gonadal hormones.

  • Prenatal stress increases dopamine D2 receptors in limbic areas of adult offspring.
  • Stress reduces dopamine release in the prefrontal cortex after amphetamine stimulation.
  • Norepinephrine release increases in the prefrontal cortex of stressed adult offspring.
  • Dopamine uptake changes persist from prepuberty through adulthood.
  • Transcription factors Nurr1 and Ptx3 show high vulnerability to prenatal stress.
low2015-01-01 · The Journal of clinical endocrinology and metabolism

A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue.

Monticone S, Bandulik S, Stindl J, Zilbermint M, Dedov I, Mulatero P, Allgaeuer M, Lee CC, Stratakis CA, Williams TA, Tiulpakov A

A rare genetic mutation in the KCNJ5 gene causes severe hyperaldosteronism by triggering a signaling cascade that activates NR4A2 expression. This activation directly increases aldosterone production, leading to high blood pressure and low potassium levels in affected infants.

  • The condition stems from a KCNJ5 mutation, not an NR4A2 mutation.
  • NR4A2 acts as a downstream messenger for aldosterone production here.
  • Symptoms include severe hypertension and hypokalemia starting in infancy.
  • This mechanism is specific to adrenal gland function, not brain development.
low2014-12-20 · Journal of molecular and cellular cardiology

NOR-1 modulates the inflammatory response of vascular smooth muscle cells by preventing NFκB activation.

Calvayrac O, Rodríguez-Calvo R, Martí-Pamies I, Alonso J, Ferrán B, Aguiló S, Crespo J, Rodríguez-Sinovas A, Rodríguez C, Martínez-González J

NOR-1 reduces inflammation in blood vessel cells by blocking a key inflammatory pathway (NFκB), which may help protect against vascular disease. This effect was seen in human cells and mice, suggesting NOR-1 could be a target for treating inflammation-related conditions.

  • NOR-1 reduces inflammation in blood vessel cells
  • It blocks NFκB, a major driver of inflammation
  • Less inflammation was seen when NOR-1 was increased
  • This effect was confirmed in human cells and mice
  • May help protect blood vessels from inflammatory damage
low2014-12-17 · Addiction biology

Regulation of dopaminergic markers expression in response to acute and chronic morphine and to morphine withdrawal.

García-Pérez D, Núñez C, Laorden ML, Milanés MV

Morphine dependence and withdrawal alter dopamine marker levels in rat brains, a process linked to changes in the transcription factors Nurr1 and Pitx3. This study demonstrates how these specific proteins regulate dopamine neuron activity in response to drug exposure and withdrawal in an animal model.

  • The study uses rats, not humans, to investigate morphine effects on dopamine pathways.
  • Nurr1 and Pitx3 levels increase during morphine dependence and withdrawal in rats.
  • These changes correlate with increased dopamine transporters and receptors in reward brain areas.
  • Findings suggest Nurr1 helps dopamine neurons adapt to chronic drug exposure.
  • This is basic molecular biology research with no direct clinical application for NR4A2 syndrome.
low2014-12-15 · Medical hypotheses

The NR4A nuclear receptors as potential targets for anti-aging interventions.

Paillasse MR, de Medina P

This paper proposes that NR4A receptors help delay aging by improving mitochondrial function and DNA repair. It suggests these receptors could be targets for treating age-related diseases but provides no clinical data or specific evidence for NR4A2-related syndrome.

  • NR4A receptors act as nutrient sensors that boost mitochondrial health.
  • These receptors assist in DNA repair mechanisms within cells.
  • The authors hypothesize NR4A targets could delay aging processes.
  • No human trials or specific NR4A2 syndrome data are presented.
low2014-12-11 · Stroke

NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke.

Merino-Zamorano C, Hernández-Guillamon M, Jullienne A, Le Béhot A, Bardou I, Parés M, Fernández-Cadenas I, Giralt D, Carrera C, Ribó M, Vivien D, Ali C, Rosell A, Montaner J

High levels of NURR1 in the blood are linked to a higher risk of bleeding complications when stroke patients receive clot-busting therapy. This study identifies NURR1 as a marker for vascular damage during ischemic stroke treatment rather than a factor in NR4A2-related developmental syndromes.

  • NURR1 levels rise in blood vessels after stroke and clot-busting drug treatment.
  • High baseline NURR1 predicts symptomatic bleeding complications from r-tPA therapy.
  • Silencing NURR1 reduces inflammation and protects blood vessel cells in mouse models.
  • This research focuses on acute stroke outcomes, not developmental NR4A2 syndromes.